Truist raised the firm’s price target on Privia Health (PRVA) to $27 from $24 and keeps a Buy rating on the shares after its Q3 earnings beat. The company has had record new provider signings year-to-date, which gives the management great visibility heading into 2025, the analyst tells investors in a research note.
Don't Miss Our New Year's Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PRVA:
- Privia Health price target raised to $29 from $26 at Canaccord
- Privia Health price target raised to $21 from $19 at Barclays
- Privia Health Group Reports Strong Q3 2024 Results
- Privia Health reports Q3 adjusted EPS 20c, consensus 5c
- Privia Health raises 2024 revenue view to high end of $1.60B-$1.675B view